Key Takeaways
- Shares of Eli Lilly declined 3% Monday following an analyst’s identification of a liver failure incident in FDA adverse event records associated with Foundayo, its oral GLP-1 medication
- The incident concerned a 56-year-old man; Lilly quickly refuted the connection, stating the case was unrelated to Foundayo
- Several Wall Street analysts characterized the market reaction as excessive and recommended purchasing shares at the lower price
- Foundayo debuted last month and has already been prescribed to 20,000 patients, with 80% being first-time GLP-1 users
- The pharmaceutical giant posted 125% year-over-year Mounjaro revenue growth reaching $8.6B and 80% Zepbound growth totaling $4.1B in recent quarterly results
Shares of Eli Lilly experienced approximately a 3% decline Monday morning after Evercore ISI’s Umer Raffat identified a hepatic failure incident within the FDA Adverse Event Reporting System (FAERS) connected to Foundayo, the pharmaceutical company’s recently introduced oral GLP-1 treatment.
The incident in question involved a 56-year-old man and potentially took place on or prior to April 15. The adverse event submission reached the FDA on April 30.
LLY shares traded around $934 during early Monday sessions before experiencing a partial rebound. Meanwhile, competitor Novo Nordisk (NVO) saw its stock appreciate roughly 2% following the disclosure.
Raffat emphasized that viewing this single case independently would be inappropriate. He pointed out that hepatic failure reports have surfaced across the broader GLP-1 drug category — with Ozempic showing 33 documented cases, Wegovy with 15, Mounjaro recording 30, and Zepbound noting 2.
The analyst suggested the “onus is on LLY” to conduct thorough and expedient evaluations of liver-related cases to prevent market uncertainty, particularly considering previous liver toxicity questions surrounding other oral GLP-1 compounds, including a Pfizer candidate.
Lilly responded swiftly to the situation. Following internal review, the pharmaceutical company rejected the report’s validity, concluding the case had no connection to Foundayo.
Wolfe analyst Alexandria Hammond supported Lilly’s assessment. She characterized the pre-market decline as “overdone” and indicated she would purchase shares amid the weakness.
Bernstein’s Christian Moore shared this perspective. He argued that overlooking a liver toxicity signal seemed improbable considering the extensive clinical trial data compiled for Foundayo, and similarly expressed his intention to buy during the dip.
Foundayo’s hepatic safety profile has undergone extensive evaluation through numerous studies, including the comprehensive 2,800-patient ACHIEVE-4 trial, which specifically examined hepatic safety at the FDA’s directive and identified no concerning safety signals.
Foundayo’s Launch Demonstrates Robust Initial Performance
Foundayo entered the market last month and has already accumulated 20,000 patients. A particularly significant detail: 80% of these patients represent new entrants to the GLP-1 drug category, indicating the oral formulation is broadening market reach rather than simply shifting patients from injectable alternatives.
Foundayo possesses a practical advantage compared to Novo Nordisk’s oral Wegovy formulation — it doesn’t require fasting conditions, allowing patients greater flexibility in incorporating the medication into their daily schedules.
Lilly is simultaneously making headway in expanding provider awareness and securing placement within major pharmacy distribution networks.
Lilly’s Fundamental Performance Stays Robust
The stock decline occurred despite Lilly delivering impressive quarterly performance metrics the previous week. Mounjaro revenue surged 125% year-over-year to $8.6 billion while Zepbound increased 80% to reach $4.1 billion.
Lilly commands approximately 60% of the U.S. GLP-1 drug market, supported partially by head-to-head clinical trial results demonstrating superior weight reduction outcomes compared to rival medications.
The pharmaceutical company maintains an active pipeline with additional weight management candidates in various development stages.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
